Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

Triple Negative Breast Cancer Drug Development Digital Summit – April 28-29, 2021
Session: Uncovering the Latest Targeted Therapy Approaches – April 29, 2021

Angus M. Sinclair, PhD, VP, Immuno-oncology Research
IGM Biosciences, Inc., 325 E Middlefield Road, Mountain View, CA 94043

TNBC Summit 2021 Sinclair

Posted in publications.